Related Experiment Video
Updated: Aug 15, 2025
08:02
Generation of Local CA1 γ Oscillations by Tetanic Stimulation
Published on: August 14, 2015
9.2K
Gamma Oscillations and Potassium Channel Modulation in Schizophrenia: Targeting GABAergic Dysfunction
Stephen J Kaar1,2,3, Judith F Nottage4, Ilinca Angelescu1,5
1Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Clinical EEG and Neuroscience
|January 2, 2023
Summary
A novel drug, AUT00206, targeting Kv3.1/3.2 potassium channels, reduced abnormal frontal gamma power in schizophrenia patients. This suggests a potential new treatment for gamma oscillation abnormalities linked to schizophrenia symptoms.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Gamma-aminobutyric acid (GABAergic) interneuron dysfunction is linked to gamma power abnormalities and schizophrenia symptoms.
- Voltage-gated potassium 3.1/3.2 (Kv3.1/3.2) channels on GABAergic interneurons are crucial for gamma oscillation generation.
- Targeting Kv3.1/3.2 channels may enhance GABAergic function and modulate gamma oscillations in schizophrenia.
Purpose of the Study:
- To investigate the effect of a novel Kv3.1/3.2 channel modulator, AUT00206, on resting-state frontal gamma power in individuals with schizophrenia.
Main Methods:
- A study involving patients with schizophrenia assessed the impact of AUT00206 on frontal gamma power (35-45 Hz).
- Correlational analysis was performed between gamma power and positive symptom severity using the Positive and Negative Syndrome Scale (PANSS).
Main Results:
- A significant positive correlation was observed between frontal gamma power and PANSS positive symptom severity (n=22, r=0.613, P<.002).
- Treatment with AUT00206 resulted in a significant reduction in frontal gamma power from baseline (t13=3.635, P=.003).
Conclusions:
- The Kv3.1/3.2 potassium channel modulator AUT00206 shows promise in addressing gamma oscillation abnormalities in schizophrenia.
- These findings provide initial evidence for AUT00206 as a potential therapeutic agent for schizophrenia.
Related Concept Videos
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
842
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
842
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
512
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
512
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
397
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
397
01:20Antiepileptic Drugs: Potassium Channel Activators
242
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
242
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.4K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.4K
01:26Psychosis: Goals of Pharmacotherapy
185
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
185